The prognostic role of a gene signature from tumorigenic breast-cancer cells
View abstract on PubMed
Summary
This summary is machine-generated.A new 186-gene invasiveness gene signature (IGS) accurately predicts survival in breast cancer and other tumors. Combining the IGS with the wound-response (WR) signature further improves prognostic accuracy for breast cancer patients.
Area Of Science
- Oncology
- Genomics
- Cancer Biology
Background
- Breast cancers harbor a CD44+CD24-/low cell population with enhanced tumorigenic potential.
- This subpopulation exhibits distinct gene-expression profiles compared to normal breast cells.
Purpose Of The Study
- To identify a gene signature associated with cancer invasiveness and patient survival.
- To evaluate the prognostic value of this signature in breast cancer and other malignancies.
Main Methods
- Gene-expression profiling of CD44+CD24-/low breast cancer cells versus normal breast epithelium.
- Development of a 186-gene invasiveness gene signature (IGS).
- Association analysis of IGS with overall survival and metastasis-free survival in multiple cancer types.
Main Results
- The IGS significantly correlated with survival outcomes in breast cancer, independent of clinical factors.
- IGS stratified high-risk breast cancer patients into good and poor prognostic categories.
- IGS demonstrated prognostic value in medulloblastoma, lung, and prostate cancers, with enhanced accuracy when combined with the wound-response (WR) signature.
Conclusions
- The IGS is a robust predictor of metastasis-free and overall survival across diverse tumor types.
- The combination of IGS and WR signature offers improved clinical outcome prediction for breast cancer.